Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04173585
Title TEAM-Trial: Targeting Epigenetic Therapy Resistance in AML With Bortezomib (TEAM)
Acronym TEAM
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors University Hospital Heidelberg
Indications
Therapies
Age Groups: adult | senior
Covered Countries DEU


No variant requirements are available.